Cisplatin: a review of toxicities and therapeutic applications.
about
Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomicsSynthetic lethality in lung cancer and translation to clinical therapiesRiboflavin ameliorates cisplatin induced toxicities under photoilluminationEffect of dicycloplatin, a novel platinum chemotherapeutical drug, on inhibiting cell growth and inducing cell apoptosisClinical Translation of Nanomedicine.Therapeutic drug-induced platelet apoptosis: an overlooked issue in pharmacotoxicology.Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.The Flavonoid Apigenin Ameliorates Cisplatin-Induced Nephrotoxicity through Reduction of p53 Activation and Promotion of PI3K/Akt Pathway in Human Renal Proximal Tubular Epithelial Cells.Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro.Capecitabine plus Cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastasesMesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.Erlotinib resistance in lung cancer: current progress and future perspectives.Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met.Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fissionRecent advances of cocktail chemotherapy by combination drug delivery systems.Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcomaPRKAR2B plays an oncogenic role in the castration-resistant prostate cancer.Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.Intralesional therapy for psoriasis.Liposomes, a promising strategy for clinical application of platinum derivatives.Application of liposomal technologies for delivery of platinum analogs in oncology.The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.Vitamin d receptor, retinoid x receptor, ki-67, survivin, and ezrin expression in canine osteosarcoma.Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs.Amelioration of cisplatin-induced nephrotoxicity by grape seed extract and fish oil is mediated by lowering oxidative stress and DNA damage.An oxovanadium(IV) complex protects murine bone marrow cells against cisplatin-induced myelotoxicity and DNA damage.Evaluation of nanoparticle delivered cisplatin in beagles.Dimethyl sulfoxide inactivates the anticancer effect of cisplatin against human myelogenous leukemia cell lines in in vitro assays.Potential nephroprotective effects of the Chinese herb Angelica sinensis against cisplatin tubulotoxicity.Combination of Sasa quelpaertensis Nakai leaf extract and cisplatin suppresses the cancer stemness and invasion of human lung cancer cells.Exploring the potential of flunarizine for Cisplatin-induced painful uremic neuropathy in ratsProtective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro.Hearing disorders in cats.MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.Novel synthetic protective compound, KR-22335, against cisplatin-induced auditory cell death.
P2860
Q26822552-5364B8EC-33EB-4282-99D0-658E2A3F1340Q28072904-0C2C7C15-7E05-4CD0-A45E-3B6B2574DE6CQ28483167-DF0585BD-0F02-4641-9BC5-2844E75B458EQ28485137-5B21302B-9F2E-4FFE-9F5B-32F7E1C6D353Q30355939-4E018EBD-377A-4059-B9B4-58FCC60E1A33Q33412254-995F3BCE-3A9F-4B5F-BFC3-84B14FF0686CQ34269549-6DC8D61C-CEAB-4D16-A50F-30D50A71CB3AQ34377003-C8E29756-E0A1-4A50-895F-AEF224A981CFQ34465240-6B9E9351-C796-4BD3-871A-E027FDD31273Q35159856-01B469EE-F502-4064-BB98-EB7ED2C67025Q35171274-F8929CA8-9D3F-4DFE-B229-8F77C4DFFA41Q35680762-235CB7E6-E81A-434C-AB00-3621390AB234Q35892472-4DDFB7FA-2511-49BE-9EB9-A4AA50F9E725Q36153465-B0ACDD8D-4B75-4C79-A2FE-62D25C7A5CF0Q36500869-366E30B0-DD10-42C6-B6A6-9E22A5096BABQ36605522-B086728F-E8E7-4040-879F-C076970CCC2AQ36852674-C3289724-E718-4D75-AF48-4BE5E39CE323Q36948510-1A67409E-2895-41EC-8E04-3537D72D18EEQ37099682-5AED3C25-4330-497C-8B5B-21F92C9DFF10Q37206908-287AA709-928B-438B-8EE6-F5CC16390289Q37366864-05DEBFB6-F887-459B-AD77-F5529AAFD000Q37701551-262F50D8-2C81-4FA5-8DDB-350892B373F6Q37709328-37FFBEB0-A074-4919-930E-C8F85A81E7D0Q37990555-53365F74-D0A5-49DB-B8E6-D0D457EFF8FDQ38087423-4D52110C-CA31-4D5D-A5F3-E3FB538EFFD8Q38136184-6470D190-BF4F-42D5-8E53-C9F9DFB81026Q38179019-7FA106BD-5C42-48DF-B1D1-CF01AD0FBC2CQ38398402-495AB1CC-052B-4D05-9DF4-29E15DA5C3A8Q38590768-0C9560D6-A1D8-4EDD-9C6A-6CB3C27471B6Q38598007-F7A1E311-514D-4150-939A-BF70FA3E0345Q38792860-ADA530E8-74B4-4850-A27E-31978BE7EE2DQ38847283-D64F3FEC-0195-41C6-BF6D-14D2586EC38CQ38864648-4ABBA4A3-BAC3-4D5B-99C0-ADF1A047C5C5Q38930073-5DC2E921-E765-4DC3-9332-98663F0543C4Q38994079-878B5CFB-7092-45A1-9433-09864D0BD1ECQ39015742-1B45FDEB-21C7-4DCC-9148-825E06C9B414Q39071852-3C4B339D-502A-4EC7-85BA-2E80C1F2F2D7Q39154836-03E13987-FAB8-4D6B-B536-2F94C7F27C77Q39210882-86B1A6B0-3C3B-4969-A654-A534B84B1703Q39214696-D2841114-A213-42FD-84E3-E2391DA93569
P2860
Cisplatin: a review of toxicities and therapeutic applications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cisplatin: a review of toxicities and therapeutic applications.
@en
Cisplatin: a review of toxicities and therapeutic applications.
@nl
type
label
Cisplatin: a review of toxicities and therapeutic applications.
@en
Cisplatin: a review of toxicities and therapeutic applications.
@nl
prefLabel
Cisplatin: a review of toxicities and therapeutic applications.
@en
Cisplatin: a review of toxicities and therapeutic applications.
@nl
P2093
P2860
P1476
Cisplatin: a review of toxicities and therapeutic applications.
@en
P2093
P2860
P356
10.1111/J.1476-5829.2007.00142.X
P577
2008-03-01T00:00:00Z